Esanex Inc.

Industry · 12 registered clinical trials.

Status	Trial	Phase	Started
Terminated	Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL Cancer	Phase 1	2017-02-07
Withdrawn	Safety and Activity of SNX-5422 Plus Ibrutinib in CLL Cancer	Phase 1	2017-02-02
Terminated	Study of SNX-5422 in TP53 Null Cancers Cancer	Phase 2	2016-03-01
Completed	Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies Cancer	Phase 1	2014-02-01
Completed	Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors Cancer	Phase 1	2014-02-01
Completed	Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors Cancer	Phase 1	2013-11-01
Terminated	Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Cancer	Phase 1 / Phase 2	2013-04-01
Completed	Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma Cancer	Phase 1	2013-03-01
Completed	Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies Cancer	Phase 1	2012-05-01
Completed	Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas Solid Tumor Malignancy, Lymphoid Malignancy (Lymphoma and CLL), Leukemia	Phase 1	2008-03-01
Completed	Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies Hematologic Neoplasms	Phase 1	2008-01-01
Completed	Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies Cancer	Phase 1	2007-06-01